Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2001

01-10-2001 | Review

Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis

Authors: Helen J Knowles, Adrian L Harris

Published in: Breast Cancer Research | Issue 5/2001

Login to get access

Abstract

The microenvironmental hypoxia that arises as a consequence of the development of a solid tumour also acts to promote tumour growth. Hypoxia induces the expression of key components of the angiogenic and apoptotic signalling cascades, the glycolytic pathway and various cell-cycle control proteins. At the cellular level it mediates the infiltration and accumulation of tumour-associated macrophages within avascular tumour regions. Complex interactions between tumour cell and macrophage hypoxia-regulated gene products and their associated pathways form the basis for the hypoxic promotion of tumourigenesis and malignant progression.
Literature
1.
Helmlinger G, Yuan F, Dellian M, Jain RK: Interstitial pH and pO2 gradients in solid tumours in vivo: high resolution measurements reveal a lack of correlation. Nat Med. 1997, 3: 177-182.CrossRefPubMed
2.
Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW: Patterns and variability of tumour oxygenation in human soft tissue sarcomas, cervical carcinomas and lymph node metastases. Int J Radiat Oncol Biol Phys. 1995, 32: 1121-1125. 10.1016/0360-3016(95)00106-9.CrossRefPubMed
3.
Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res. 1989, 49: 6449-6465.PubMed
4.
Hill SA, Pigott KH, Saunders MI, Powell MEB, Arnold S, Obeid A, Ward G, Leahy M, Hoskin PJ, Chaplin DJ: Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer. 1996, 74: S260-S263.
5.
Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna G, Wu JM, Bernhard EJ: The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumours expressing activated H-ras. Cancer Res. 2001, 61: 2289-2293.PubMed
6.
Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Beau JM, Prosnitz LR, Dewhirst MW: Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56: 941-943.PubMed
7.
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relation to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988, 14: 831-838.CrossRefPubMed
8.
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupek P: Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56: 4509-4515.PubMed
9.
Dicato M, Duham C, Berchem G, Ries F: Clinical benefit from erythropoietin. Curr Opin Oncol. 2000, 12: 297-302. 10.1097/00001622-200007000-00004.CrossRefPubMed
10.
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992, 359: 843-845. 10.1038/359843a0.CrossRefPubMed
11.
Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000, 6: 389-395. 10.1038/74651.CrossRefPubMed
12.
Rak J, Yu JL, Klement G, Kerbal RS: Oncogenes and angiogenesis: signaling three-dimensional tumour growth. J Invest Dermatol Symp Proc. 2000, 5: 24-33. 10.1046/j.1087-0024.2000.00012.x.CrossRef
13.
Maxwell PH, Dachs GU, Gleadle JM, Hicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci USA. 1997, 94: 8104-8109. 10.1073/pnas.94.15.8104.CrossRefPubMedPubMedCentral
14.
Ryan HE, Lo J, Johnson RS: HIF-1α is required for solid tumour formation and embryonic vascularisation. EMBO J. 1998, 17: 3005-3015. 10.1093/emboj/17.11.3005.CrossRefPubMedPubMedCentral
15.
Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit M, Johnson RS: Hypoxia-inducible factor-1α is a positive factor in solid tumour growth. Cancer Res. 2000, 60: 4010-4015.PubMed
16.
Gupta K, Kshirsagar S, Li W, Gui W, Ramakrishnan S, Gupta P, Law PY, Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signalling. Exp Cell Res. 2000, 247: 495-504. 10.1006/excr.1998.4359.CrossRef
17.
Baek JH, Jang J-E, Kang C-M, Chung H-Y, Kim ND, Kim K-W: Hypoxia-induced VEGF enhances tumour survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000, 19: 4621-4631. 10.1038/sj/onc/1203814.CrossRefPubMed
18.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379: 88-91. 10.1038/379088a0.CrossRefPubMed
19.
Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994, 54: 2095-2097.PubMed
20.
Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ: Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995, 55: 1811-1816.PubMed
21.
Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA. 2000, 97: 9082-9087. 10.1073/pnas.97.16.9082.CrossRefPubMedPubMedCentral
22.
Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumours. Cancer Research. 2001
23.
Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ: Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene. 2000, 19: 6297-6305. 10.1038/sj/onc/1204012.CrossRefPubMed
24.
Semenza GL, Roth PH, Fang H-M, Wang GL: Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994, 269: 23757-23763.PubMed
25.
Mathupala SP, Heese C, Pederson PL: Glucose catabolism in cancer cells. J Biol Chem. 1997, 36: 22776-22780. 10.1074/jbc.272.36.22776.CrossRef
26.
Kalra VK, Shen Y, Sultana C, Rattan V: Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Am J Physiol. 1996, 271: H2025-H2034.PubMed
27.
Turner L, Scotton C, Negus R, Balkwill F: Hypoxia inhibits macrophage migration. Eur J Immunol. 1999, 29: 2280-2287. 10.1002/(SICI)1521-4141(199907)29:07<2280::AID-IMMU2280>3.0.CO;2-C.CrossRefPubMed
28.
Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogensis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56: 4625-4629.PubMed
29.
Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE: Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularised areas of breast cancers. J Pathol. 2000, 192: 150-158. 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.3.CO;2-7.CrossRefPubMed
30.
Wycoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh C, Ratcliffe PJ, Harris AL: Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res. 2000, 60: 7075-7083.
Metadata
Title
Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis
Authors
Helen J Knowles
Adrian L Harris
Publication date
01-10-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr314

Other articles of this Issue 5/2001

Breast Cancer Research 5/2001 Go to the issue

Commentary

BRCA2 and homologous recombination

Commentary

Mutations in normal breast tissue and breast tumours

Research article

Hormone replacement therapy use dramatically increases breast oestrogen receptor expression in obese postmenopausal women

Commentary

Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients

Commentary

The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression

Research article

The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits